PMID- 16354748
OWN - NLM
STAT- MEDLINE
DCOM- 20060321
LR  - 20071114
IS  - 0305-7453 (Print)
IS  - 0305-7453 (Linking)
VI  - 57
IP  - 2
DP  - 2006 Feb
TI  - Immune reconstitution inflammatory syndrome: more answers, more questions.
PG  - 167-70
AB  - The institution of highly active antiretroviral therapy (HAART) in HIV-infected 
      patients restores protective immune responses against a wide variety of pathogens 
      and dramatically decreases mortality. In a subset of patients receiving HAART, 
      immune reconstitution is associated with a pathological inflammatory response 
      leading to substantial short-term morbidity and even mortality. The past several 
      years have seen marked advances in our clinical understanding of the immune 
      reconstitution inflammatory syndrome (IRIS), but many questions remain. This 
      article summarizes recent data on clinical risk factors for the development of 
      IRIS. A consistent finding from multiple groups is that IRIS develops in a 
      substantial percentage of HIV-infected patients who have an underlying 
      opportunistic infection and receive HAART. As the use of HAART stands to markedly 
      increase over the next several years, optimal care of patients receiving HAART 
      will need to incorporate monitoring for and treating complications of IRIS.
FAU - Shelburne, Samuel A
AU  - Shelburne SA
AD  - Department of Medicine, Section of Infectious Diseases, Baylor College of 
      Medicine, and Department of Medicine, Michael E. DeBakey Veterans Affairs Medical 
      Center, Houston, TX 77030, USA.
FAU - Montes, Martin
AU  - Montes M
FAU - Hamill, Richard J
AU  - Hamill RJ
LA  - eng
GR  - K12 RR17665/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20051214
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
SB  - IM
CIN - J Antimicrob Chemother. 2006 Nov;58(5):1094; author reply 1094-5. PMID: 16980294
MH  - Antiretroviral Therapy, Highly Active/*adverse effects
MH  - HIV Infections/*complications/pathology
MH  - Humans
MH  - Inflammation/*etiology/pathology
MH  - Syndrome
RF  - 33
EDAT- 2005/12/16 09:00
MHDA- 2006/03/22 09:00
CRDT- 2005/12/16 09:00
PHST- 2005/12/16 09:00 [pubmed]
PHST- 2006/03/22 09:00 [medline]
PHST- 2005/12/16 09:00 [entrez]
AID - dki444 [pii]
AID - 10.1093/jac/dki444 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2006 Feb;57(2):167-70. doi: 10.1093/jac/dki444. Epub 2005 
      Dec 14.